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Fibrin structure contributes to the regulation of the 
fibrinolytic rate. As the fibrin fiber size is decreased, 
the fibrinolytic rate also decreases. Fibrin structure 
was altered by either changing the ratio of thrombin 
to fibrinogen, Le. altering the assembly rate or by 
adding a fibrin assembly inhibitor, iopamidol. Changes 
in the fibrinolytic rate were followed by measuring the 
time dependence of the decrease in the fiber mass/ 
length ratio during fibrinolysis. A measure of the over- 
all fibrinolytic rate was determined from the decrease 
in the massllength ratio versus time. An 8-fold reduc- 
tion in the fibrinolytic rate was  seen on decreasing the 
mass/length ratio from 2.7 % 10” daltons/cm to 0.5 x 
10” daltons/cm. It is shown that thin fibrin fibers  have 
a decreased rate of conversion of plasminogen to plas- 
min by tissue plasminogen activator and that thin fi- 
brin fibers are lysed more slowly than thick fibrin 
fibers. 
The physiologic dissolution of an in vivo fibrin  clot  results 
from  an  interdependent process  involving the  interaction of 
tissue plasminogen activator  (tPA)’  and plasminogen in  inti- 
mate  contact  on a fibrin surface (1). The  adsorption of tPA 
and plasminogen on  the  fibrin fiber  surface allows the neces- 
sary contact needed to affect optimal activation rates for 
plasmin  production  and  spatial  proximity of the  fibrin  sub- 
strate.  Fibrin plays a dual role in  this  series of events.  Not 
only does it  enhance  tPA  activation,  it  also  acts  as  substrate 
for plasmin. 
The conversion of plasminogen to plasmin can occur by 
several different mechanisms, but it appears that the most 
important in uiuo activator is tPA (2). tPA, M, = 70,000, is 
present  in  plasma  as a  single-chain serine  protease,  but  pro- 
teolytic cleavage of the Agr275-Ile276 bond  in  tPA by plasmin 
yields a  disulfide-linked two-chain enzyme (3). The  presence 
of fibrin greatly accelerates  the  activation of plasminogen by 
tPA  and hence can  exert a  regulatory  influence over plasmin- 
ogen activation (4-6). Molecular details of the tPA-fibrin 
interaction  are  not completely understood.  Structural  features 
in  the  D-domain of fibrin  contained in the  peptide sequence 
are crucial to  tPA  binding (6). Within  this sequence, 
the lysine  side chain at distal  to  the  outer disulfide 
ring,  has been  implicated  for the  tPA  binding (7). Voskuilen 
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et al. (7) postulate  that  fibrin  formation exposes this  latent 
tPA-binding  site  in  the D-domain and  thus  facilitates  plas- 
minogen activation. 
Plasmin, a  disulfide-linked two-chain serine enzyme, is 
formed from the  limited proteolysis of Arg560Va15fi1 bond in 
plasminogen (8). The heavy chain of plasmin contains the 
lysine-binding sites which are necessary for the binding of 
plasmin  to  fibrin.  These  sites  are found in  the so-called  kringle 
regions (9). The light  chain of plasmin  contains  the  serine- 
active site. Several different forms of plasmin can be pro- 
duced, depending  on  the  presence of inhibitors.  Under  phys- 
iological conditions, Glu, plasmin  predominates (10). In  the 
absence of inhibitors, cleavage of the  amino  terminal  portion 
of plasmin occurs  between  Argfi7-Metfi8, L y ~ ~ ~ - L y s ~ ~ ,  or Lys7‘- 
Val7* to produce three  similar  forms of plasmin collectively 
called “Lys-plasmin” (11). 
Recent  experiments  have also shown that  the  number of 
tPA-binding sites (12) and fibrinolytic rates for thin fibers 
(13) is  dependent  on  fibrin  structure.  In  this  report,  our aim 
was to manipulate fibrin fiber structure in an effort to  ex- 
amine  the effect of fibrin fiber diameter  and  density  on  both 
the  enzymatic  action of plasmin  on  fibrin  and  the  activation 
of plasminogen  by tPA. 
MATERIALS AND  METHODS 
Fibrinogen  Purification-Human plasma was thawed  in  the  pres- 
ence of 25 KIU/ml  aprotinin  and 10 pM D-phenylalanyl-N-[4- 
[(aminoiminomethyl)amino]-l-(chloracetyl)butyl]-~-prolinamide 
18O(PPACK). Plasminogen  and  fibronectin were removed by a  lysine 
and  gelatin  affinity  columns respectively. Plasminogen-  and fibronec- 
tin-free fibrinogen was then  obtained by ammonium  sulfate precipi- 
tation  and  DEAE  ion-exchange  chromatography. Coagulable protein 
was greater  than  95%. Fibrinogen concentration was measured  spec- 
trophotometrically using an extinction coefficient of 1.51 mg/ml. 
Human  a-thrombin was a gift from  Dr. Frank  Church  (University of 
North  Carolina). Highly  purified  plasminogen (9.6 casein  units/ml) 
was purchased  from  Kabi  Vitrum  and  two-chain  tissue plasminogen 
activator  (Duteplase,  Burroughs Wellcome, Research  Triangle  Park, 
NC, 3.1 X lo5 IU/ml) was  a gift from Dr.  Henry Burger. 
Fibrin Gel Assembly-Fibrin gels were formed directly in 1-cm 
polystyrene cuvettes by mixing purified fibrinogen solutions (1 g/ 
liter)  with buffered solutions of a-thrombin.  Unless otherwise stated, 
the final thrombin concentration was 1 NIH units/ml. Gels were 
formed a t  0.05 M Tris,  pH 7.4, 5 mM CaCI2, and  the ionic strength 
adjusted  to 0.15 with NaC1. All measurements were made at  37 “C. 
Fibrinogen was added a t  time 0 to  the buffered human  a-thrombin 
solution  containing specified additives  and  the  turbidity (7)  followed 
as a function of time. The first  appearance of the gel is indicated as 
an increase in  turbidity.  Fibrin  structure was modified in two  different 
ways. The first  method was to  alter  the assembly rate by varying the 
ratio of thrombin  to fibrinogen (14).  In  these  experiments  the  fibrin- 
ogen concentration was held constant and the concentration of (Y- 
thrombin varied from 1 NIH  unit/ml  to 0.05 NIH unit/ml. A  second 
method used  a fibrin assembly inhibitor  to  alter fibrin structure  (13). 
In these experiments fibrin structure was altered by addition of a 
radio  contrast  agent, iopamidol (Squibb), which induces formation of 
thin fibrin fibers, to  the polymerizing solution. In all experiments, 
ionic strength  and  variation  in polymerization  buffers were carefully 
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controlled so that  the effect of changes  in fibrin structure could  he 
isolated and  studied. All fibrinogen was quantitatively  converted  to 
fibrin regardless of the  mass/length ratio. 
Turbidity  Measurements-Turbidity measurements were made at  
37 "C with a Cary 118C spectrophotometer  as previously described 
(14).  The  mass/length  ratio for thin  fibrin fibers,  where the  diameter 
of the fiber is less than  the wavelength of the  incident light, can be 
calculated from the wavelength dependence of turbidity  (14) as given 
by: 
7((88/15)?r3n(dn/dC)*C~)/NX3 (Eq. 1) 
T is the sample turbidity, n is  the refractive  index, C is the  concentra- 
tion in grams/liter, is the  mass/length  ratio, N is Avogadro's 
number,  and X is  the wavelength of the  incident light. A plot of 7 
uersus X is linear, if the fibers are sufficiently thin, and permits 
calculation of the  mass/length  ratio. Refractive  index measurements 
were  made in a temperature-controlled  Bausch  and Lombe  Abbe-3L 
refractometer. Refractive index increments were made in a Brice- 
Phoenix differential refractometer  that was equipped with a HeNe 
laser  as  the light  source. 
Plasmin Assay-A two-stage assay was used to  measure  the  plas- 
min  concentration.  Purified  human plasminogen from  Kabi  Vitrum 
was  reconstituted  to 9.6 casein  units/ml  with  water.  In  the  first stage, 
fibrin was formed and plasminogen activated by tPA.  To  this  end, 
fibrin gels were prepared by adding the prewarmed plasminogen 
solution  (37 ") to a degassed solution of 0.05 M Tris,  pH 7.4, 5 mM 
CaCl,, 1 NIH unit/ml human a-thrombin, 40 ng/ml tPA, and a 
variable amount of iopamidol. The fibrin assembly reaction was 
initiated by the addition of fibrinogen. The final concentration of 
fibrinogen was 1 g/liter  and plasminogen  was 0.008 casein  units/ml. 
Ionic  strength was adjusted  to 0.15 with 1 M NaC1. The samples  with 
negative and positive controls were incubated at  37 "C for 50 min 
after which time  the  reaction was stopped  with  hirudin  (Sigma)  and 
the fibrin clot removed. The second stage required addition of the 
plasmin synthetic substrate. After removal of the fibrin clot, an 
aliquot of the  supernatant was taken  and  then  diluted  with a 80/20 
volume ratio of 4.0 mM chromogenic substrate: S-2251 (CH-D-Val- 
Leu-Lys-pNA) from Kabi Vitrum. The concentration of plasmin 
generated by the conversion of plasminogen to  plasmin by tPA for a 
given  fiber size was obtained by comparison of the  absorbance of the 
clot  supernatant a t  405 nm  to  the  plasmin  standard curve.  A standard 
curve  in  the presence of fibrin for the hydrolysis of S-2251 by plasmin 
was  obtained by serial dilution of Glul-plasmin  and  determination of 
t.he absorbance at  405 nm. Independent assays using chromogenic 
substrates showed no effect of iopamidol on thrombin or plasmin 
activity. 
RESULTS 
In these experiments fibrin assembly and fibrinolysis is 
detected by changes  in  turbidity.  The weight  average  mass/ 
length  ratio for the  fibrin fibers is  then  calculated  from  the 
measured  turbidity.  The  mass/length  ratio  is  related  to  the 
fiber diameter  and  the fiber's mass  density.  Thus,  the  rate of 
fibrin assembly or fibrinolysis can  be  determined by a plot of 
the change  in  the  fibrin fiber mass/length  ratio as a function 
of time (14-20). The objective of these  experiments is to show 
that fibrin  structure  as  evaluated by mass/length  ratio  meas- 
urements influences the fibrinolytic rate. 
Fig. 1 shows the sequence of fibrinogen activation by throm- 
bin,  the  fibrin assembly resulting from the  production of fibrin 
monomers,  and fibrinolysis  caused  by tPA, plasminogen, and 
plasmin.  Fibrin assembly is  indicated by an increase in  the 
mass/length  ratio  and fibrinolysis by a decrease in  the  mass/ 
length  ratio.  Changes in the  fibrin fiber structure  in  this figure 
are made by varying the ratio of thrombin to fibrinogen 
thereby altering the assembly rates and ultimately fibrin 
structure  (14,21). After addition of thrombin,  the  mass/length 
ratio increases indicating fibrin formation. Gel formation 
continues  to grow over a  period of 5-20 min  as evidenced by 
the continued increase in  the  mass/length  ratio.  The  initial 
increase in the  mass/length  ratio is followed by a  decrease as 
fibrinolysis  occurs. The negative  slope of a plot of the  mass/ 
length  ratio uersus time  estimates  the fibrinolytic rate.  Since 
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FIG. 1. The effect of fibrin fiber thickness on the fibrino- 
lytic rate. The fiber  diameter was changed by decreasing  the  throm- 
bin  concentration while  holding the fibrinogen concentration (1 mg/ 
ml) fixed. Thrombin  concentrations  (in NIH units/ml) were: 1 (U), 
0.5 (O), 0.2 (V), 0.1 (0), and 0.05 (0). An  increase  in  the  mass/length 
ratio  with  time  indicates  fibrin assembly and a  decrease in  the  mass/ 
length ratio  indicates fibrinolysis. As the  ratio of thrombin  to  fibrin- 
ogen was  decreased, the  maximal fiber thickness  increased  (increased 
mass/length ratio). Also, as the thrombin concentration was de- 
creased, the  initial slope  decreases as a  consequence of slower assem- 
bly rates. The initiation of fibrinolysis (tPA 40 ng/ml,  plasminogen 
0.008 CU/ml) is  indicated by a decrease in  the  mass/length ratio. The 
negative  slope in  this  portion of the  plot  is a measure of the  fibrino- 
lytic rate.  The fibrinolytic rate was slower for fibrin fibers with a low 
mass/length  ratio  (thin  fibers). If the fibrinolytic rates were identical, 
the negative  slopes would be parallel  and would not converge. 
initial slopes for fibrinolysis cannot be obtained from the 
plots because fibrin assembly may still be present  during  the 
early fibrinolytic  period, estimates for fibrinolytic rates were 
obtained from a linear fit of the mass/length ratio data 
between the  maximum  (approximately 10 min)  and  minimum 
(approximately 40 min) values. 
Three  important  features  can be seen. First,  as  the  throm- 
bin  concentration  is decreased from 1 NIH  unit/ml  to 0.05 
NIH  unit/ml,  both  the gelation time  and  the  rate of fibrin 
assembly is decreased. The slower assembly rate  is shown by 
a flatter slope  for the  ascending  portion of the curve (fibrin 
assembly) at  lower thrombin  concentrations. Second, as  the 
concentration of thrombin decreases in the five separate 
experiments shown in Fig. 1, the  maximum  mass/length  ratio 
increases  indicating  that  thicker  fibrin fibers are produced as 
the assembly process is slowed (21). Third, the fibrinolytic 
rate  can be observed as a  decrease in  the  mass/length  ratio, 
which is  seen  in  the  terminal  portion of the  mass/length  ratio 
uersus time plots (22). The importance of this figure with 
respect to  fibrinolysis is that the thicker fibers, which are 
formed at lower thrombin  concentrations, have  a  more rapid 
decrease in the mass/length ratio per unit time than the 
thinner fibers, i.e. thicker fibers are lysed faster  than  thinner 
fibers. The  steeper slope indicates a faster fibrinolytic rate.  If 
the fibrinolytic rates for each different fiber thickness were 
the  same,  then a series of parallel curves with  similar slopes 
would been seen. 
A decrease in  the fibrinolytic rate induced by thin fibrin 
fibers is also shown in Fig. 2. In Fig. 2 fibrin structure is 
changed by  a different  method.  Here  the  addition of iopamidol 
causes  the  formation of thin  fibrin fibers  (23). In  these  exper- 
iments, the concentrations of thrombin and fibrinogen are 
held constant. As the fibers are made thinner by increasing 
the  concentration of iopamidol  (24) from 0 mM to 25.7 mM, 
flatter slopes and slower fibrinolytic rates  are observed similar 
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Frc. 2. The  effect of fibrin fiber thickness on the fibrino- 
lytic rate; thrombin, 1 NIH unit/ml, and fibrinogen, 1 mg/ml, 
were held constant. Thin fibers were induced by addition of iopam- 
idol.' Iopamidol concentrations (mM) correspond to: none (O), 5 (O), 
10 (V), and 29 (0). Fibrinolysis is indicated by a decrease in the 
mass/length ratio. The fibrinolytic rate decreased, i.e. a flatter slope, 
as the fibers were made thinner by iopamidol. 
t o  those shown  in Fig. 1. Thus,  these  experiments also  suggest 
that  the fibrinolytic rate  is slower for thin fibers. In  separate 
experiments  no effect of iopamidol was observed on  the  hy- 
drolysis of S-2251 by plasmin,  indicating  that iopamidol  does 
not  inhibit  plasmin. 
Since  both  the  mass/length  ratio for fibrin  monomer  and 
for fibrin  fibers are known, the  number of fibrin  monomers 
contained  within  the  fiber  cross  section  can  be  calculated (14, 
22). Further, the rate at which the fibrin monomers are 
removed  from the fiber cross  section  during  the fibrinolytic 
process  can  be  determined  from  the  time  dependence of the 
decrease  in  the  mass/length ratio. In Fig. 3 the  rate of removal 
of  fibrin monomers  per  minute  from  the fiber cross  section  is 
plotted  against  the  number of fibrin  monomers  present  within 
the fiber  cross-section at  the  beginning of fibrinolysis. Data 
for  this  plot  are  obtained from Figs. 1 and 2. The slope of the 
plot is obtained by a linear regression and provides  a  simple 
rate  constant for the process that  is  calculated  to be 3.2 x 
min". Thus, the fibrinolytic rate over the range of 
experimental  conditions  studied is linear  with respect to  the 
fibrin monomer density  within  the fiber. 
Fig. 4  shows the effect of the  fiber  diameter  on  the  conver- 
sion of plasminogen to plasmin by tPA with fibrin as a 
promoter. In these experiments fibrin structure is modified 
by iopamidol (23). Measurements were made at 37 "C. A  two- 
stage  assay was used. In  the  first  stage fibrinogen is added to 
a buffered solution of a-thrombin, tPA, and plasminogen. 
Fibrin assembly followed by fibrinolysis is  permitted  to  pro- 
ceed as previously  described. The action of thrombin is 
quenched by hirudin.  In  the second stage  the clot is removed 
and  the  concentration of plasmin  measured by hydrolysis of 
s-2251  at 37 "C. As the fibers are made thinner by increasing 
the concentration of iopamidol  from 0 to 30 mM, the  concen- 
tration of plasmin produced is decreased  from 0.0085 to 0.0018 
casein units/ml indicating the significance of fibrin fiber 
structure in the  rate of conversion of plasminogen to  plasmin. 
In Figs. 1 and 2, fibrinolysis was dependent  on  the in situ 
production of plasmin by the  action of tPA  on plasminogen. 
A decrease in  the fiber size was accompanied by a  decreased 
rate of plasmin  production.  Experiments shown  in Fig. 5 were 
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Frc. 3. The  effect of the number of fibrin monomers within 
the fiber on the fibrinolytic rate was calculated from Fig. 2. 
The number of fibrin monomers  within  the fibrin  fiber was calculated 
by dividing the fiber mass/length  ratio by the fibrin  monomer  mass/ 
length  ratio. The initial  number of fibrin  monomers/fiber  cross 
section was determined from the  maximum  mass/length  ratio value. 
The  time  interval considered for the fibrinolytic rate calculation was 
chosen between the  maximum  mass/length  ratio value and  the  break 
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FIG. 4. The  effect of fibrin fiber mass/length ratio on the 
conversion of plasminogen (0.008 casein  units/ml)  to plasmin 
by tPA (40 ng/ml). The fibrin  fiber mass/length  ratio is controlled 
by the  concentration of iopamidol. As the fibers were made thinner, 
the  amount of plasmin produced was decreased. 
repeated  under  the  same  conditions  with  one xception: tPA 
and plasminogen were replaced by plasmin. This  alteration 
of the procedure was designed to bypass the plasminogen 
activation step. No longer dependent on the generation of 
plasmin,  thin  fibrin fibers were shown to  be a  poorer substrate 
for plasmin  than  thick fibers. Fig. 5 demonstrates  that in the 
presence of the  same  amount of plasmin,  thin fibers have a 
slower fibrinolytic rate  than  thicker fibers. In  fact, for  fibers 
that  are only  a few monomers  thick, i.e. a mass/length  ratios 
of less than 0.5 X 10l2 daltons/cm, a protective effect may be 
present. Hyper-rigidity, i.e. unusually stiff fibrin gels, has 
been observed early  in fibrinolysis and may be related  to  this 
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FIG. 5 .  Effect of fibrin fiber mass/length ratio on fibrinol- 
ysis initiated by plasmin. In these experiments plasmin 0.008 
casein units/ml was substituted for tPA  and plasminogen, so that 
plasminogen activation was not  required for plasmin  production as 
in Figs. 1 and 2. The fiber mass/length  ratio was  decreased  by addition 
of iopamidol (mM) as follows: 0 (O), 5 (O), 10 (V), 20 (0). The 
fibrinolytic  rate decreased as the  mass/length  ratio decreased until a 
critical  mass/length  ratio of 0.5 X 10" daltons/cm was reached. No 
fibrinolysis  occurred for fibers with a mass/length  ratio  less that  this 
value  until  the fiber diameter grows larger to  the  apparent  critical 
limit of approximately 0.5 X 10" daltons/cm. 0.5 x 10' daltons/cm 
corresponds  to a  fiber approximately 2 fibrin monomers  thick. 
protective effect (25). It is possible that fibrinogen, which is 
less susceptible to plasmin, may be incorporated into  the gel 
during early gel formation.* 
DISCUSSION 
Fibrin structure varies, depending on the conditions  under 
which it is assembled (14-21). The material  properties,  such 
as gel rigidity, fiber thickness, fiber mass density, pore size 
(the distance between the fibers within the gel), fiber branch 
point density, and stiffness of the fibers between the branch 
points are  determined by the fibrin structure. Different phys- 
iologic or pathologic conditions may govern the structural 
features of fibrin. These features  determine the mechanical 
rigidity of the gel (17,24,26), how easily other macromolecules 
can diffuse within the gel (27), and how long the gel may 
survive. The  internal  structure of fibrin influences the diffu- 
sion  rates of macromolecules, such as plasminogen or tPA, 
within fibrin. For example, we have recently shown by holo- 
graphic relaxation spectroscopy that  the diffusion of aggre- 
gated IgG is influenced by pore size within fibrin (27), but 
that  the diffusion coefficient for monomeric IgG and albumin 
is not. 
Fibrinolysis is also influenced by fibrin structure. Fibrin 
structure  has been implicated in  determining the number of 
tPA-binding sites on fibrin (12) and resistance to plasmin 
attack (13). Ping and Gaffney (12) have observed that pro- 
duction of thick fibrin fibers is associated with adsorption of 
more tPA  and faster fibrinolytic rates. Studies in this report 
show that plasmin production by tPA activation of plasmin- 
ogen is proportional to  the fibrin fiber thickness, which may 
provide greater surface for assembly of the fibrinolytic com- 
plex. As the concentration of the plasmin converted is in- 
' J. McDonagh, unpublished  data. 
creased, the  rate of fibrinolysis is expected to escalate. With 
thin fiber production, a decrease in the plasmin concentration 
and slower fibrinolytic rate is expected. 
In addition to a decrease in tPA-binding  sites on thin fibrin 
fibers, a decrease in  plasmin-binding  sites may also exist, as 
suggested by the occurrence of much slower fibrinolytic rates 
when plasmin is substituted for tPA and plasminogen as in 
Fig. 5. 
Thus,  at least two effects of the  thin fibers on fibrinolysis 
are observed. One is a slower rate of plasmin production and 
the other is a slower rate of fibrin digestion by plasmin. The 
possible thread linking  these two events may  be derived from 
a decrease in binding sites for plasmin in thin fibers, or limited 
access to the binding sites by plasmin in thin fibers or a 
combination of both.  Preliminary  experiments using an  en- 
zyme-linked immunosorbent assay technique to detect the 
presence of plasmin bound to fibrin  indicate that less plasmin 
is found on clots composed of thin fibers compared to clots 
formed from thick  fiber^.^ Ping and Gaffney (12) have found 
a decreased number of binding sites in gels formed under 
conditions that produce thin fibrin fibers. In  this report, the 
rate of fibrinolysis with time is noted to change during the 
early time points, especially for the thick fibers, which also 
supports the observation that  the fiber diameter influences 
the fibrinolytic rate. 
It is possible to calculate the number of fibrin monomers 
present  in the fibrin fiber cross-section using the mass/length 
ratio data. For example in Fig. 2 after 10 min of assembly 
time in the absence of iopamidol, the maximal fiber thickness 
occurs and is composed of an average of about 35 fibrin 
monomers in the fiber cross-section (Fig. 3). Beyond 10 min 
the fibrinolytic process begins to disassemble the fibers, and 
at 35 min the average fiber cross-section is about 2-3 fibrin 
monomers thick. Approximately 1.3 monomers/min are re- 
moved from the fiber cross-section in  these fibers. In  contrast, 
if the  thin fibers are  studied (induced by  20 mg/ml iopamidol) 
the  starting number of fibrin monomers in the cross-section 
is an average of 5.25 and by 35 min is also reduced to 2-3 
fibrin monomers in the fiber cross- section. For these thin 
fibers, approximately 0.09 monomer/min is removed from the 
fiber cross-section. Thus,  the  rates of monomer removal are 
approximately two orders of magnitude slower for the  thin 
fibers compared to  the thicker fiber. When the fiber cross- 
section is reduced to 4-5 fibrin monomers, a common fibrin- 
olytic rate occurs. 
Additional support for these  experimental observations is 
derived from the decrease fibrinolysis of fibrin formed from 
the dysfibrinogen Chapel Hill 111, which forms clots composed 
of extremely thin fibers. Fibrinogenolysis of the dysfibrinogen 
Chapel Hill I11 is normal, but fibrinolysis was drastically 
delayed (28). Another  abnormal fibrinogen, fibrinogen Dusart, 
has a delay in  lateral association with production of very thin 
fibrin fiber similar to fibrinogen Chapel Hill I11 and also has 
a decreased binding of plasminogen (29). 
The basis for the slower rates is not completely understood 
at present. These  data indicate that  the fibrin  structure at  the 
beginning of the fibrinolytic process determines the kinetic 
rate; the greater  mass/length  ratio, the faster the fibrin dis- 
solution. Since tPA  and plasminogen binding may occur dur- 
ing fibrin assembly, the fiber structural features at  the end of 
fibrin assembly may determine the number of potential  bind- 
ing sites for the fibrinolytic complex. It is probable that  thin 
fibers possess fewer plasmin binding sites, which may be just 
a function of the decrease surface for the thin fibers. We 
postulate that  thin fibers do not provide either an optimal 
D. A. Gabriel, unpublished  data. 
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surface for the tPA-plasminogen-fibrin complex binding or 
for plasmin binding. This phenomenon is possible due to 1) a 
decrease in the number of binding sites resulting from the 
smaller surface area of thin fibers or 2) steric  factors caused 
by the increased curvature of the  thin fibers that prohibit 
stable interaction between tPA and its binding site. This 
effect does not appear to be the result of changes in the 
diffusion coefficient for molecules diffusing within the fibrin 
gel, since photon correlation spectroscopy and holographic 
relaxation spectroscopic measurements of albumin and im- 
munoglobulin G within the fibrin gel are not changed by 
similar modifications in fibrin (27, 30). Pulsed-field gradient 
nuclear magnetic resonance spectroscopy has been used to 
further validate these measurements in polyacrylamide gels 
(31). The radius of curvature in the thin fibers may be 
important since Nieuwenhuizen et al. (6) have shown a  bind- 
ing  site for tPA on the y-chain.  Thus, it is possible that  the 
spatial relation between the tPA-binding  site on the y-chain 
and the plasminogen-binding site on the a-chain may be 
critically distorted in thin fibers. Alternative explanations 
include a solution statistical factor of a decreased collision 
rate between plasmin and fibrin based on the fiber size since 
thin fibers make a smaller collisional target. Further, the 
composition of fibrin with respect to desA-, desAA-, or 
desAABB fibrin monomers or the occasional inclusion of a 
fibrinogen molecule may be important to tPA and plasmin 
binding. Thus, surface provided by fibrin for the fibrinolytic 
process is important  as  a means to regulate the fibrinolytic 
process. 
In combination, these  experiments show that  the decreased 
fibrinolytic rate is not only a  result of a slower production of 
plasmin for thin fibers, but also that thin fibers are more 
resistant  to plasmin digestion than thick fibers. 
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